Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Brazil ETF (EWZ) vs Merck & Co., Inc. (MRK) Price & Performance

Ishares Msci Brazil ETFTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Ishares Msci Brazil ETF vs Merck & Co., Inc. — how do they compare? Ishares Msci Brazil ETF trades at $33.83, while Merck & Co., Inc. trades at $133.17 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while Ishares Msci Brazil ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.

EWZMRK
Sector
Broad Market / FactorHealth
52-Week High
$41.75$131.84
52-Week Low
$27.36$77.60
Market Cap
$321.77B
Enterprise Value
$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Brazil ETF

EWZ, the iShares MSCI Brazil ETF, trades at $34.04, down 3.27% on the day. The technical outlook is bearish based on moving averages, though oscillators suggest potential for a near-term bounce. Recent news highlights institutional interest, with Empowered Funds LLC and Allspring Global Investments increasing positions in Q2 2026, while analysts debate the fund's value relative to competitors like FLBR due to its higher expense ratio.

The outlook for EWZ hinges on Brazil's economic trajectory, particularly interest rate cuts and commodity prices. Opportunities exist if Brazil's growth accelerates, but risks include U.S. tariff impacts on Brazilian exports and inconsistent dividend payouts reliant on volatile commodity stocks like Petrobras and Vale.

Merck & Co., Inc.

MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.

MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ishares Msci Brazil ETF

EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.

Read more on EWZ

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK